指南与共识淋巴瘤

淋巴结外周T细胞淋巴瘤诊断与治疗中国专家共识(2025)

[Chinese expert consensus on the diagnosis and management of nodal peripheral T-cell lymphoma (2025)].
指南 / 共识 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

淋巴结外周T细胞淋巴瘤在我国发病率高、侵袭性强、预后差,各亚型分子特征和临床表现差异大,传统化疗疗效有限。中国临床肿瘤学会淋巴瘤专家委员会和中华医学会血液学分会淋巴细胞疾病学组组织专家制定本共识,旨在规范诊疗并推动新型疗法的临床研究和应用。

要点

  • 淋巴结PTCL在我国常见,侵袭性强、预后差,各亚型差异大。
  • 传统化疗疗效有限,靶向药物及多药联合策略正在改变治疗模式。
  • 共识旨在推动规范诊疗及新型疗法的临床研究和应用。

核心结论

  • 淋巴结PTCL侵袭性强、预后差,传统化疗疗效有限,靶向药物及多药联合策略正在改变初始、维持及复发后治疗模式。

研究设计与样本

  • 由中国临床肿瘤学会淋巴瘤专家委员会和中华医学会血液学分会淋巴细胞疾病学组组织专家制定共识。

主要发现

  • 淋巴结PTCL是我国除结外NK/T细胞淋巴瘤外最常见的PTCL,发病率高于西方国家。
  • 各亚型分子特征和临床表现差异大,传统化疗疗效有限。
  • 靶向药物及多药联合策略显著改善了部分患者预后。

临床怎么用

  • 推动我国临床医师对淋巴结PTCL的进一步规范诊疗。
  • 促进新型疗法的临床研究和应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphomas (PTCL) are a common type of non-Hodgkin lymphoma in China, with a higher incidence compared to Western countries. Apart from extranodal NK/T-cell lymphoma, nodal PTCL is the most prevalent subtype in China. Nodal PTCL is highly aggressive with a poor prognosis. Significant differences in molecular characteristics and clinical manifestations are observed among various subtypes, and the efficacy of conventional chemotherapy is limited. In recent years, the application of targeted therapies has significantly improved outcomes for some patients and is changing treatment paradigms for initial, maintenance, and relapsed disease. Based on these advancements, the Lymphoma Expert Committee of Chinese Society of Clinical Oncology and Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association have organized a panel of experts to develop this consensus, aiming to promote standardized diagnosis and treatment of nodal PTCL among clinicians in China, as well as to facilitate clinical research and application of novel therapies. 外周T细胞淋巴瘤(peripheral T-cell lymphomas, PTCL)是我国常见的非霍奇金淋巴瘤,发病率高于西方国家。除结外NK/T细胞淋巴瘤外,我国最常见的PTCL是淋巴结PTCL。淋巴结PTCL多数侵袭性强、预后差,各亚型分子特征和临床表现差异大,传统化疗疗效有限。近年来靶向药物以及多药联合治疗策略的应用显著改善了部分患者的预后,也正在改变患者的初始、维持及复发后治疗模式。基于此,中国临床肿瘤学会(CSCO)淋巴瘤专家委员会和中华医学会血液学分会淋巴细胞疾病学组组织相关专家制定了本共识,旨在推动我国临床医师对淋巴结PTCL的进一步规范诊疗及新型疗法的临床研究和应用。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese expert consensus on the diagnosis and management of nodal peripheral T-cell lymphoma (2025)]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41486653. doi:10.3760/cma.j.cn121090-20250808-00364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。